All articles tagged with #cancer vaccine
MimiVax's experimental cancer vaccine SurVaxM failed to meet its primary endpoint in a Phase 2b trial for glioblastoma, showing a median overall survival of 22.8 months versus 20.3 months for placebo. However, the drug demonstrated statistically significant survival benefits in patients aged 65 and under, prompting the company to seek FDA approval.
MimiVax reported that its experimental vaccine SurVaxM failed to meet the primary endpoint in a phase 2 trial for glioblastoma, an aggressive brain cancer. While overall survival did not significantly improve across the full study group, data for patients aged 65 and younger showed a meaningful survival benefit, leading the company to pursue FDA approval.
Personalized mRNA cancer vaccines from Moderna and Merck are showing promising late-stage results in cancers such as melanoma, pancreatic and brain tumors by training the immune system to recognize tumor-specific mutations. When combined with immunotherapy, these vaccines have reduced cancer recurrence and extended remission in some patients. More than 120 trials since the early 2000s illustrate ongoing progress and optimization of targets and combinations, though bringing an mRNA cancer vaccine to the public could take 10–15 years amid funding shifts.
Moderna and Merck reported positive Phase 3 data for intismeran autogene, a personalized cancer vaccine, in combination with Keytruda for melanoma, showing longer cancer-free survival versus Keytruda alone. The readout prompted stock upgrades and higher price targets for both companies, highlighting the potential of a market-of-one approach despite uncertainties about market size and applicability to other cancers. The vaccine’s roughly six-week manufacturing window enables concurrent treatment with Keytruda, raising the prospect of a new growth driver if similar results extend to other solid tumors; however, success in one cancer type does not guarantee broader approvals.
Moderna executives remain confident in the personalized cancer vaccine intismeran autogene and plan to share more late-stage trial details with Merck at an upcoming conference. The company is refocusing on renal cell carcinoma and pulling back from bladder cancer, aiming to unlock a multibillion-dollar market, but investors still await full trial results before pricing in the program.
Topline results from a large trial show Moderna and Merck’s cancer vaccine, intismeran autogene, reduced recurrence or spread of surgically removed melanoma, signaling a milestone after years of doubt and pandemic-related hurdles—though some scientists urge waiting for fuller data and longer follow-up before declaring a definitive breakthrough.
An mRNA cancer vaccine has achieved a late-stage success—Moderna and Merck's personalized vaccine intismeran autogene reduced melanoma recurrence when paired with Keytruda—pointing to a new frontier in cancer treatment and prevention, but persistent misinformation about mRNA technology, including the 'turbo cancer' narrative, threatens to erode public trust and slow adoption; experts say proactive, transparent communication, clinician training, and public health messaging are essential to translate scientific progress into real-world benefits.
Moderna and Merck reported a personalized mRNA cancer vaccine used with Keytruda that reduced melanoma recurrence and spread in a trial of more than 1,000 patients, with five-year data from earlier results showing about a 50% drop in recurrence and a 59% drop in spread versus Keytruda alone; if approved, thousands of melanoma patients could benefit in the first years, and trials in other cancers (lung, bladder, kidney, pancreatic, stomach) are ongoing with results expected in the coming years.
Moderna’s personalized cancer vaccine mRNA-4157 (intismeran autogene) paired with Merck’s Keytruda hit key Phase 3 melanoma endpoints, delivering a 49% reduction in recurrence or death versus Keytruda alone and sparking a 177% one‑day stock surge before shares retraced about 20% as investors took profits; Moderna’s pipeline spans nine Phase 2/3 studies across melanoma, NSCLC, bladder and kidney cancers, despite a $950 million settlement and a norovirus program setback, while Merck’s KEYTRUDA franchise remains a critical driver for oncology growth.
A concise roundup notes SpaceX delaying its launch schedule, a pause on new tariffs, and developments in a cancer vaccine, reflecting ongoing activity across aerospace, trade policy, and healthcare.
Merck and Moderna reported that a personalized neoantigen mRNA vaccine, intismeran, added to Merck's Keytruda in adjuvant melanoma slowed recurrence and metastasis in a Phase 3 trial, signaling a potential new class of cancer immunotherapies, though detailed data have yet to be released.
Phase I trial of the KRAS-targeting vaccine mKRAS-VAX in 20 high‑risk individuals with pancreatic abnormalities showed 90% developed a robust immune response against six KRAS mutations, with memory cells detectable up to two years; no pancreatic cancer or high‑risk lesions developed during a median follow‑up of 16.5 months, and some precursor cysts regressed, supporting larger trials to test cancer interception.
Moderna co-founder Kenneth Chien remains bullish on mRNA’s potential, predicting an mRNA cancer vaccine could reshape oncology and lift the entire field, even as past Moderna–AstraZeneca deals failed to deliver the planned drugs.
A UCLA-led immunotherapy approach for glioblastoma exposes a patient’s white blood cells to tumor cells outside the brain, then reinfuses them as a vaccine. From 2003–2019 trials, 331 patients received the vaccine and 20–25% survived years longer, with 2023 JAMA Oncology results prompting further study of why some patients respond. Researchers are examining biomarkers like MGMT methylation and the gut microbiome to predict benefit. The work, led by Dr. Linda Liau, has earned recognition in medicine and reflects her personal drive born from family experience with brain cancer.
A phase 2b trial (KEYNOTE-942) shows adding the personalized mRNA vaccine intismeran to pembrolizumab after melanoma surgery reduces recurrence or death by 49% over five years. The combo also lowers distant metastasis risk by 59% and yields 92.2% overall survival versus 71.3% with pembrolizumab alone. Five-year follow-up found 68.8% cancer-free in the combo group vs 50.9% in controls. The study, conducted in the US and Australia with 107 patients in the combo arm and 50 in control, reported manageable side effects and is guiding a phase 3 trial, with Moderna and Merck funding.